Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101492 | 1.00 | GPR119 (0.50) | GPR119FPR2FPR3ESRRBESR1 | |
| SCHEMBL26101871 | 0.84 | USP30 (0.47) | GPR119JAK2JAK1 | |
| SCHEMBL26101877 | 0.84 | USP30 (0.47) | GPR119JAK2JAK1 | |
| SCHEMBL24670655 | 0.82 | GPR119 (0.49) | GPR119FPR2FPR3 | |
| SCHEMBL29990492 | 0.82 | GPR119 (0.49) | GPR119FPR2FPR3 | |
| SCHEMBL24319582 | 0.80 | GPR119 (0.60) | GPR119FPR2FPR3ESRRBESR1 | |
| SCHEMBL8477717 | 0.78 | GPR119 (0.48) | GPR119 | |
| SCHEMBL3488062 | 0.78 | GPR119 (0.79) | GPR119FPR2ESRRBESR1ESRRA | |
| SCHEMBL26102494 | 0.77 | MCHR1 (0.37) | GPR119 | |
| SCHEMBL16825784 | 0.77 | GPR119 (0.52) | GPR119FPR2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | GPR119 3223/4885FPR2 2547/4885FPR3 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.